Form 4 holding
Director
Evommune, Inc.
- Security class
- Common Stock
- Shares / value
- 17,609
- Estimated value
- $376,480
- Report date
- 02 Jun 2026
- Price
- $21.38
- Ownership
- Direct
David E. Cohen
Insider Reports History
- Reporting-owner location
- Palo Alto, CA
- Latest reporting-owner signature
-
/s/ Gregory S. Moss, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for David E. Cohen
Form 4 holding
Director
Timber Pharmaceuticals, Inc.
- Security class
- Common Stock, par value $0.001 per share
- Shares / value
- 6,100
- Estimated value
- $9,937
- Report date
- 15 Apr 2023
- Price
- $1.63
- Ownership
- Direct
Form 4 holding
Director
Evommune, Inc.
- Security class
- Stock Option (Right to buy)
- Shares / value
- 15,673
- Estimated value
- Report date
- 02 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Timber Pharmaceuticals, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 4,100
- Estimated value
- Report date
- 15 Apr 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Evommune, Inc.
- Security class
- Series Seed Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 07 Nov 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Kadmon Holdings, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 09 Nov 2021
- Price
- $5.54
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
Insider Reports Filed by David E. Cohen
4
EVMN
Evommune, Inc.
- Report period
- 02 Jun 2026
- Transactions
- 3
- Transaction value
- -$123,094
- Accepted by SEC
- 03 Jun 2026, 20:03
- Role
- Director
- Next action
- Open filing details
4
Evommune, Inc.
- Report period
- 07 Nov 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Nov 2025, 16:17
- Role
- Director
- Next action
- Open filing details
4
Evommune, Inc.
- Report period
- 05 Nov 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Nov 2025, 16:15
- Role
- Director
- Next action
- Open filing details
3
Evommune, Inc.
- Report period
- 05 Nov 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Nov 2025, 20:02
- Role
- Director
- Next action
- Open filing details
4
Timber Pharmaceuticals, Inc.
- Report period
- 15 Apr 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Apr 2023, 11:32
- Role
- Director
- Next action
- Open filing details
4
Timber Pharmaceuticals, Inc.
- Report period
- 15 Apr 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 Apr 2022, 12:59
- Role
- Director
- Next action
- Open filing details
4
Kadmon Holdings, Inc.
- Report period
- 09 Nov 2021
- Transactions
- 4
- Transaction value
- -$2,194,844
- Accepted by SEC
- 09 Nov 2021, 16:37
- Role
- Director
- Next action
- Open filing details
4
Timber Pharmaceuticals, Inc.
- Report period
- 01 Jul 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jul 2021, 16:06
- Role
- Director
- Next action
- Open filing details
4
Kadmon Holdings, Inc.
- Report period
- 12 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 May 2021, 16:10
- Role
- Director
- Next action
- Open filing details